SCHEMBL14955153

SCHEMBL14955153

Nc1c(C(=O)O)sc2nc3c(c(-c4ccco4)c12)CCC3

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.84
HTT P42858 3/20 0.84
HSD17B10 Q99714 2/20 0.84
USP2 O75604 1/20 0.84
PTK2B Q14289 1/20 0.84
L3MBTL1 Q9Y468 1/20 0.84
EEF2K O00418 9/20 0.79
MEN1 O00255 5/20 0.77
KMT2A Q03164 5/20 0.77
LMNA P02545 4/20 0.77
ALDH1A1 P00352 7/20 0.74
NPSR1 Q6W5P4 3/20 0.74
KDM4E B2RXH2 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
HPGD P15428 2/20 0.63
TP53 P04637 1/20 0.63
TSHR P16473 1/20 0.63
MAPK1 P28482 1/20 0.63
BRCA1 P38398 1/20 0.63
MAPK10 P53779 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14955168 0.98 MAPT (0.84) MAPTHTTHSD17B10USP2PTK2B
SCHEMBL429326 0.92 MAPT (1.00) MAPTHTTHSD17B10USP2PTK2B
SCHEMBL430534 0.89 MAPT (1.00) MAPTHTTHSD17B10USP2PTK2B
SCHEMBL13392915 0.85 MAPT (0.74) MAPTHTTHSD17B10USP2PTK2B
SCHEMBL13392946 0.85 MAPT (0.74) MAPTHTTHSD17B10USP2PTK2B
SCHEMBL18186056 0.84 EEF2K (0.86) MAPTHTTHSD17B10USP2PTK2B
SCHEMBL13186408 0.84 KMT2A (0.86) MAPTHTTHSD17B10USP2PTK2B
SCHEMBL18537648 0.84 ALDH1A1 (0.88) MAPTHTTHSD17B10USP2PTK2B
SCHEMBL13392908 0.83 MAPT (0.74) MAPTHTTHSD17B10USP2PTK2B
SCHEMBL14969396 0.83 ALDH1A1 (1.00) MAPTHTTHSD17B10USP2PTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181568-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Siga Technologies, Inc. (US) 2017-06-21 EP disclosed
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2017-05-04 US disclosed
EP-2400845-B1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECH INC (US) 2017-02-22 EP disclosed
US-20160152635-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2016-06-02 US disclosed
US-9301949-B2 Thienopyridine derivatives for the treatment and prevention of dengue virus infections SIGA TECHNOLOGIES, INC. (US) 2016-04-05 US disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections TTPA, TPMT, SLC19A2 MAPT 85/4885HTT 2588/4885HSD17B10 3757/4885
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS TTPA, TPMT, SLC19A2 MAPT 85/4885HTT 2588/4885HSD17B10 3757/4885
US-20160152635-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS TTPA, TPMT, SLC19A2 MAPT 138/4885HTT 2608/4885HSD17B10 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.